Bavarian Nordic A/S

Research Bavarian Nordic A/S (BV3A) on Bullrun: valuation model: 18.6% undervalued, market cap EUR 1.73B, P/E 11.3. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerBV3A
• ExchangeF
• CountryDenmark
• SectorHealthcare
• IndustryBiotechnology
• CurrencyEUR
• Valuation signal18.6% undervalued
• Market capEUR 1.73B
• P/E11.3
• Financial periodQ4 2025
• RevenueEUR 1.45B
• Net income-EUR 298.80M
• Free cash flowEUR 403.62M
• Gross margin38.7%

Valuation Snapshot

Bullrun's latest valuation model marks Bavarian Nordic A/S as 18.6% undervalued; latest market cap is EUR 1.73B; P/E is 11.3.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever.

Frequently asked questions

Is Bavarian Nordic A/S overvalued or undervalued?

Bullrun's valuation model currently marks Bavarian Nordic A/S as 18.6% undervalued.

What is Bavarian Nordic A/S's market cap?

Bavarian Nordic A/S's market capitalization is EUR 1.73B.

What is Bavarian Nordic A/S's P/E ratio?

Bavarian Nordic A/S's price-to-earnings (P/E) ratio is 11.3.

What does Bavarian Nordic A/S do?

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name;